A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo
Study Type/Phase: Phase III
Status: Not Recruiting
The purpose of this trial is to evaluate the safety and effectiveness of Keytruda® (pembrolizumab) for patients with early stage breast cancer who need systemic treatment before and after surgery. Keytruda is an immunotherapy drug that has been approved by the FDA for other types of cancer. This trial will see how well Keytruda works when combined with chemotherapy and endocrine therapy, compared to these treatments alone, for this type of breast cancer. In this trial, Keytruda or a placebo will be added in a randomized fashion to the patient’s regular treatment regimen for breast cancer. This patient population is at higher risk for repeated occurrences of breast cancer and this trial gives them another treatment option.
Speak with your doctor to determine whether you meet the following criteria for participation in this study.
|Inclusion Criteria||Exclusion Criteria|